Introduction
Obesity is characterized as a condition of chronic, low-grade inflammation. Obese individuals exhibit mildly, but significantly elevated systemic concentrations of acute-phase proteins, cytokines and chemokines, which can be reduced by weight loss. [1] [2] [3] [4] [5] [6] Growing evidence indicates that this immune activation is involved in the development of the metabolic syndrome and related disorders like cardiovascular disease and type 2 diabetes. 7, 8 Recent studies investigated the link between obesity and inflammation and demonstrated that obesity is associated with substantial macrophage infiltration into adipose tissue. [9] [10] [11] However, it is still unknown how this inflammatory process is induced and maintained. It has been hypothesized that overnutrition causes a metabolic overload with increased demands on the endoplasmic reticulum (ER) and on the mitochondria. 12 This can lead to ER stress and excess production of reactive oxygen species, which interfere with intracellular signaling cascades and might thereby stimulate the release of proinflammatory mediators (Wellen and Hotamiligil 12 and references therein). Adipocytes represent an important source of immune mediators 13, 14 including chemokines with potent chemoattractant properties for specific leukocyte subsets carrying the corresponding receptors. Thus, adipocyte-expressed chemokines may be important in initiating leukocyte infiltration. 15, 16 The capacity of constitutive and regulated release of immune mediators demonstrates a considerable overlap between the biology of adipocytes and innate immune cells such as macrophages.
Chemokines represent a class of low molecular weight proteins crucially involved in leukocyte recruitment and activation. One of the first chemokines to be identified was interferon (IFN)g-inducible protein-10 (IP-10/CXCL10). 17 IP-10 is a CXC chemokine with chemoattractant properties for activated T cells, monocytes, NK cells, dendritic cells and eosinophils. 18, 19 IP-10 expression has been described in several cell types, including neutrophils, monocytes, endothelial cells, fibroblasts and keratinocytes (Dufour et al. 20 and references therein; 21, 22 ). IP-10 may be implicated in the development of cardiovascular disease, as it is expressed by endothelial cells, smooth muscle cells and macrophages within human atherosclerotic plaques, but not within the normal vessel wall, 23 and as patients with coronary heart disease show an enhanced expression of IP-10. 24, 25 Positive correlations of IP-10 serum concentrations with body mass index (BMI) and other parameters of obesity have been reported in some, but not all studies, [25] [26] [27] and data regarding a potential impact of BMI on IP-10 expression on a cellular level have not been investigated. We therefore studied the possible induction of IP-10 by adipocytes. As indicated by the chemokine's name, IFNg is the main regulator of IP-10 expression. There is indeed in vitro evidence for an impact of IFNg on adipocyte function. IFNg treatment led to a profound decrease of the expression of transcription factors like peroxisome proliferator-activated receptor g (PPARg) and sterol regulatory element-binding protein-1 and increase in signal transducer and activator of transcription (STAT)-1 and STAT-3 expression. 28 These findings suggested that IFNg-regulated molecules may be expressed by adipocytes. In the current study, the following questions were addressed: (i) Do human adipocytes express IP-10? (ii) Is IP-10 release different in adipocytes from subcutaneous (s.c.), omental (o.m.) or mammary depot and does IP-10 release depend on donor BMI? (iii) Is IP-10 expression in adipocytes similarly regulated as in monocytes/macrophages by IFNg or lipopolysaccharide (LPS)? )). All subjects were free of metabolic or endocrine disease as assumed by routine laboratory investigation. The procedure for obtaining human adipose tissue was approved by the Ethical Committee of Heinrich-Heine-University Düsseldorf.
Subjects and methods

Subjects
Cell culture
Adipose tissue samples were prepared as described previously. 29 Briefly, connective tissue and visible blood vessels were removed with scissors, and fat lobules were cut into small pieces. The minced tissue was then digested in phosphate-buffered saline containing 250 U/ml collagenase (Biochrom, Berlin, Germany) and 2% bovine serum albumin (BSA) (Sigma, Munich, Germany) for 90 min at 371C in a shaking water bath. Stromal cells were collected by a 10-min centrifugation at 200 g. The supernatants with the adipocytes were aspirated and discarded. Sedimented cells were depleted of erythrocytes, filtered through a 150 mm nylon mesh to remove undigested material and filtered again through a 70 mm cell strainer to obtain a pure preadipocyte preparation. . The serum-containing medium was replaced after 16 h by serum-free DMEM/F-12 medium supplemented with 10 mg/ml human transferrin (Sigma), 66 nM human insulin (Sigma), 100 nM cortisol (Aventis Pharma, Frankfurt, Germany), 0.2 nM T 3 (triiodothyronine; Sigma) and 0.05 g/l gentamycin (Invitrogen Life Technologies, Gaithersburg, MD, USA). To induce adipose differentiation, cells were exposed to 1 mg/ml troglitazone (Sankyo Europe, Düsseldorf, Germany) and 0.5 mM isobutyl-methylxanthine (IBMX; Serva, Heidelberg, Germany) for the first 4 days. The medium was changed every other day. On day 16, approximately 45-70% of the cells acquired an adipocyte phenotype detectable by multiple cytoplasmic lipid inclusions. GPDH measurements in previous experiments indicated that the level of differentiation in adipocytes from s.c., o.m. and mammary depots was comparable.
In parallel experiments, mature adipocytes were isolated. In contrast to the aforementioned protocol, a shorter collagenase digestion of only 60 min in Krebs-Ringer phosphate buffer (KRP, pH 7.4) containing 4% BSA was performed. Cells were carefully centrifuged and washed twice with KRP, supplemented with 0.1% BSA. After a filtration step through a 250 mm nylon mesh, cells were allowed to recover from preparation for 24 h in DMEM/F12 supplemented with 2% BSA. After this period, 400 ml packed adipocytes in 4 ml DMEM/F12 þ 0.25% BSA were incubated for 24 h without further supplement or with either 1 mg/ml LPS, 1 ng/ml IFNg or 50 ng/ml interleukin (IL)-4 (R&D Systems, Minneapolis, MN, USA). Two batches of LPS from Escherichia coli 0111:B4 and E. coli 055:B5 (both from Sigma) were used. Conditioned media were stored at À201C for later analyses.
Measurement of IP-10 and adiponectin protein concentrations
Concentrations of IP-10 protein in conditioned cell culture media were assessed with a Luminex assay based on a IP-10/CXCL10 secretion by human adipocytes C Herder et al protocol of de Jager et al. 30 The Luminex technology is a microbead-based multiplexing system. Fluorophore-labeled bead sets are coated with different monoclonal antibodies that bind specific analytes, which are then detected by corresponding secondary antibodies. For the IP-10 assay, beads from Luminex Corporation (Austin, TX, USA) were used in combination with a capture antibody, a biotinylated secondary antibody and recombinant IP-10 protein for the standard curve from BD Biosciences (Heidelberg, Germany). Bound secondary antibody was labeled with a streptavidin-Rphycoerythrin conjugate from Qiagen (Hilden, Germany). Flow cytometric analysis based on a BioPlex system (Bio-Rad Laboratories, Munich, Germany) was used to detect both bead and phycoerythrin fluorescence. The limit of detection (LOD) was 9.8 pg/ml. If the IP-10 concentration was below the LOD, the sample was assigned a value of 0.5 Â LOD. Adiponectin concentrations were determined using the human adiponectin radioimmunoassay from Linco Research Inc. (St Charles, MS, USA) according to the manufacturer's instructions.
IP-10 gene expression
Total RNA was isolated using the NucleoSpin RNA II-kit (Macherey-Nagel, Düren, Germany) including DNA digestion. For reverse transcription (RT) up to 1 mg total RNA, 1 mM oligo(dT) primers, 500 mM dNTPs each, 10 U RNasin (Promega, Madison, WI, USA), 1 Â RT buffer and 4 U Omniscript Reverse Transcriptase (Qiagen) were combined in a 20 ml reaction and incubated at 371C for 1 h, followed by denaturation at 951C for 5 min. 31 Quantitative real-time polymerase chain reaction (PCR) was performed in optical reaction tubes (Applied Biosystems, Foster City, CA, USA) in 96-well microtiter plate format using the ABI PRISM 7700 Sequence Detector System (Perkin-Elmer, Foster City, CA, USA). 
Statistical analysis
For comparisons, paired, two-tailed t-tests were used. The correlation of IP-10 release by o.m. and s.c. adipocytes or of IP-10 release and donor BMI was assessed by Spearman's rank correlation test. Po0.05 was considered to be statistically significant.
Results
IP-10 release from mature human adipocytes IP-10 secretion by freshly isolated mature adipocytes was assessed using cells from o.m. and s.c. depots of 12 donors. IP-10 concentrations in conditioned media from o.m. and s.c. adipocytes reached 1317114 and 857104 pg/ml, respectively (Figure 1a) . IP-10 release from both depots in individual donors did not differ significantly (P ¼ 0.12) and was highly correlated (r ¼ 0.71; Po0.01). In comparison, adiponectin was released in much higher amounts (o.m. 39.8721.1 mg/ml, s.c. 36.2720.9 mg/ml), but also without difference between the two depots (P ¼ 0.42).
IP-10 release from o.m. adipocytes tended to be positively correlated with donor BMI (r ¼ 0.51; P ¼ 0.093; Figure 1b) , whereas the correlation between IP-10 release from s.c. adipocytes and donor BMI was much weaker (r ¼ 0.21; P ¼ 0.51; data not shown).
Stimulation of IP-10 expression and release with IFNg, but not with LPS or IL-4
In order to test whether IP-10 release from adipocytes might be upregulated by IFNg, in vitro differentiated adipocytes from three different fat depots were exposed to IFNg. Mean IP-10 concentrations in the conditioned media of unstimulated cells were below 100 pg/ml. As shown in Figure 2 
Immunofluorescence
In order to confirm the IFNg-stimulated IP-10 production, adipocytes from the s.c. abdominal adipose tissue were differentiated in vitro for 12 days and stained for IP-10. These experiments revealed that intracellular IP-10 protein was hardly detectable in lipid droplets-containing adipocytes under basal conditions (Figure 5a ), but the fluorescence intensity could be enhanced by the addition of brefeldin A (Figure 5b) , which disrupts the vesicular transport within the cells and leads to the accumulation of secretory proteins like IP-10 in the ER. IP-10/CXCL10 secretion by human adipocytes C Herder et al
Discussion
The present study identifies adipocytes as novel cellular source of the CXC chemokine IP-10/CXCL10. As demonstrated on mRNA and protein level, IP-10 is expressed constitutively in human, freshly isolated o.m. and s.c. adipocytes in most donors. In addition, IP-10 release could also be shown for in vitro differentiated mammary adipocytes. As in particular cultures of in vitro differentiated adipocytes may contain contaminating fibroblasts, macrophages or endothelial cells that could give to rise the IFNg-mediated activation of IP-10 secretion in primary cultures, [20] [21] [22] immunocytochemical studies were performed.
As summarized in Figure 5 , IFNg-induced expression of IP-10 was most prominent in differentiated adipocytes containing multiple lipid droplets. This observation cannot exclude completely the possibility that other cell types contributed to IP-10 release, but strongly suggests that our results can be attributed mainly to IP-10 release from adipocytes.
Our finding is important as the initiation of the recently described macrophage infiltration into obese adipose tissue 9-11 is still poorly understood, and the characterization of the chemokine expression pattern of adipocytes might provide an explanation for this phenomenon. It can be argued that IP-10 might not be considered a relevant candidate in this respect because of its more potent chemotactic effect on stimulated T cells compared to monocytes/macrophages. 18 However, it is conceivable that macrophages are not the only leukocyte subset to maintain adipose tissue inflammation as the analysis of samples of epicardial adipose tissue also revealed the presence of T-lymphocytes and mast cells. 33 Further studies are required to investigate which leukocytes other than macrophages accumulate in the various adipose IP-10/CXCL10 secretion by human adipocytes C Herder et al tissue depots in obesity or other endocrine conditions. The local inflammation of epicardial fat might be most important in the context of atherosclerosis. It remains to be seen how local expression of IP-10 and other chemokines in epicardial adipocytes or atheroma-associated cells 23 and leukocyte infiltration in epicardial adipose tissue modulate cardiovascular disease risk and outcome. We investigated IP-10 expression and secretion in adipocytes, so that an activation of the cells by collagenase isolation and in vitro culture cannot be excluded. The accumulation of IP-10 during the culture period and the detection of spontaneously released IP-10 in cultures with shorter recovery period after isolation (2 h instead of 24 h; data not shown) however argue against major artifacts induced by the culture conditions and confirm that isolated adipocytes express and secrete IP-10.
A second major finding of this study is the high correlation and lack of difference of IP-10 release between o.m. and s.c. cells. It is well known that there is considerable heterogeneity among the different fat depots with higher expression of immune mediators like IL-6, IL-8 or the soluble tumor necrosis factor (TNF)-a receptors in o.m. versus s.c. adipose tissue. [34] [35] [36] In most cases, however, this difference seems to be attributable to increased cytokine or chemokine expression in the stromal-vascular fraction, so that our data are in line with other studies investigating isolated adipocytes and correcting for macrophage gene expression. 37, 38 We also studied the effect of donor BMI on IP-10 release of mature adipocytes, but found only a nonsignificant trend towards increased IP-10 secretion in obese donors, whereas a statistically significant positive association between donor BMI and release of macrophage migration inhibitory factor has recently been demonstrated by us using the same methodology. 39 In contrast to fat depot and donor BMI, we could identify IFNg, but not LPS or IL-4, as potent modulator of IP-10. IFNgmediated induction of IP-10 can be seen in most IP-10-expressing cell types including monocytes/macrophages, although in dermal fibroblasts and astrocytoma cells, the induction is weak and TNFa or a combination of IFNg/TNFa are required. 21, 40 The physiological relevance of this regulation is not yet understood, as local IFNg concentrations in adipose tissue have not been investigated. Given the fact that potentially IFNg-producing T cells have been found in epicardial tissue, 33 paracrine effects of IFNg-secreting immune cells on adipocytes seem conceivable. More striking than the regulation by IFNg is the lack of IP-10 activation by LPS in mature adipocytes, as LPS is a strong stimulus for IP-10 expression in rodent macrophages and vascular smooth muscle cells. [41] [42] [43] Thus, our data indicate that the regulation of IP-10 by immunological stimuli is highly cell type-specific and underline the concept that there is a partial overlap between macrophage and adipocyte functions regarding immune marker release with important differences regarding their regulation. Interestingly, the amount of upregulation of IP-10 expression and release by IFNg was in the same magnitude of order in in vitro differentiated and mature s.c. adipocytes, although our data indicate that the induction of gene expression may be stronger in in vitro differentiated cells, whereas stimulation of IP-10 release may be more pronounced in mature cells. Further studies would be necessary to determine which impact cell differentiation might have on IP-10 expression and regulation in adipocytes. Given the evidence that circulating and local IP-10 concentrations are associated with atherosclerosis, it is interesting to note that IFNg-induced expression of IP-10 in human endothelial cells can be inhibited by antidiabetic PPARg agonists. 44 It has been described before that PPARg agonists have a profound anti-inflammatory effect and reduce serum or plasma levels of acute phase proteins, soluble CD40 ligand and TNFa, which are associated with type 2 diabetes and/or atherosclerosis. [45] [46] [47] Future studies will have to show whether antidiabetic or lipid-lowering drugs affect systemic or local IP-10 levels and what the clinical relevance of their effect on IP-10 expression is. In summary, the present study identifies human adipocytes from various fat depots as a source of IP-10, a chemokine which has been implicated in the development of atherosclerosis and other diseases. IP-10 release from freshly isolated adipocytes from o.m. and s.c. depots is highly correlated and not significantly different. In mature s.c. adipocytes, IFNg, but not LPS or IL-4, significantly enhance IP-10 expression and release, which demonstrates both similarities and differences in the regulation of IP-10 in adipocytes and innate immune cells.
